iFANN
    iFANN'da ara...
    Giriş Yap
    Ana Sayfa
    Haberler
    Videolar
    Fotoğraflar
    GIF'ler
    Keşfet
    Anketler
    Ödüller
    iFAMOUS
    Viki
    Anime
    Odalar
    Bildirimler
    Mesajlar
    Yer İmleri
    Profil
    VikiÖdülleriFAMOUSSıralamalarSektörlerİçerik Üretici ÖdülleriKullanıcı ÖdülleriŞartlarGizlilikTopluluk KurallarıKaldırma / DMCAYardımGeliştiriciler

    © 2026 iFANN

    Ana Sayfa
    Ara
    Mesajlar
    Uyarılar
    Profil

    Gönderi

    Gloriaunhinged
    Gloriaunhinged@gloriaunhinged
    💭Health💭Science

    CARv3-TEAM-E glioblastoma trial MRI results

    What showed up on the scans five days after one infusion is the part doctors are still calling jaw-dropping. Three people with recurrent glioblastoma came to Massachusetts General Hospital in early 2024, and the therapy they got, CARv3-TEAM-E, is a CAR T-cell approach that starts with each patient's own immune cells. Those cells get genetically rewired in the lab so they recognize two markers that tend to sit on glioblastoma cells. Then they go straight into the fluid spaces of the brain, and it all happens through one procedure. From there the outcomes split in ways nobody was ready for. One patient's MRI at day five showed the tumor had nearly vanished. Another patient's tumor shrank by more than 60 percent, and that reduction held for over six months. The third patient had clear tumor reduction within days. Compare that with what immunotherapy had done for this type of brain cancer before, and the speed and the size of the response are on another level entirely. The early images being described as jaw-dropping feels less like hype and more like an understatement.

    1mo

    521 Beğeni31 Beğenmeme84 Yeniden paylaşım24 Yorumlar
    ?

    Yorumlar

    Henüz yorum yok. İlk yorumu sen yap!

    Gönderi

    Gloriaunhinged
    Gloriaunhinged@gloriaunhinged
    💭Health💭Science

    CARv3-TEAM-E glioblastoma trial MRI results

    What showed up on the scans five days after one infusion is the part doctors are still calling jaw-dropping. Three people with recurrent glioblastoma came to Massachusetts General Hospital in early 2024, and the therapy they got, CARv3-TEAM-E, is a CAR T-cell approach that starts with each patient's own immune cells. Those cells get genetically rewired in the lab so they recognize two markers that tend to sit on glioblastoma cells. Then they go straight into the fluid spaces of the brain, and it all happens through one procedure. From there the outcomes split in ways nobody was ready for. One patient's MRI at day five showed the tumor had nearly vanished. Another patient's tumor shrank by more than 60 percent, and that reduction held for over six months. The third patient had clear tumor reduction within days. Compare that with what immunotherapy had done for this type of brain cancer before, and the speed and the size of the response are on another level entirely. The early images being described as jaw-dropping feels less like hype and more like an understatement.

    1mo

    521 Beğeni31 Beğenmeme84 Yeniden paylaşım24 Yorumlar
    ?

    Yorumlar

    Henüz yorum yok. İlk yorumu sen yap!